Guselkumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Guselkumab: From Plaque Psoriasis to Drug-Induced Osteoporosis
One-Sentence Summary
Guselkumab (brand name TREMFYA) is an anti-IL-23 antibody. The Evidence Pack treats plaque psoriasis as its established use, though the license records list no indication text. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but 0 clinical trials and 0 publications support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the license records; the Evidence Pack rationale identifies plaque psoriasis as an established marketed use |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 records (all under BLA761061) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the DrugBank field. The Evidence Pack’s rationale identifies guselkumab as a monoclonal antibody against the p19 subunit of IL-23. IL-23 drives Th17 differentiation and IL-17/IL-22 signaling, which underlie psoriatic skin inflammation.
The link to osteoporosis is speculative. The IL-23/IL-17 axis can influence osteoclast formation and bone remodeling, so blocking it could in theory affect bone loss. However, no trial or publication tests this in drug-induced osteoporosis, and the very high TxGNN score is a model output, not a clinical signal. Osteoporosis caused by drugs such as glucocorticoids has different drivers from psoriatic inflammation, so the similarity to the original indication is unestablished.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761061 | TREMFYA (Janssen Biotech, Inc.) | Injection | Not listed in the record |
The three license records are duplicates of the same BLA and product.
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found in the query.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature, and the mechanistic link is only speculative. The TxGNN score alone is not enough to justify moving forward.
Other predictions in the pack (not the focus of this report):
- Psoriasis (rank 3): L1 evidence with completed Phase 3 RCTs (e.g., VOYAGE 1 and 2). The pack flags this as confirmation of a known use, not a novel repurposing finding.
- Ulcerative colitis (rank 6): L1 evidence from the QUASAR Phase 3 program. The pack suggests this may already be a labeled use.
- Other Hold predictions (ranks 2, 4, 5, 7-10): All L5 with no supporting evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications (the pack marks this as a blocking gap)
- Verification of the current label and indication registry to confirm which indications are already approved
- Preclinical or mechanistic evidence for IL-23 blockade in bone loss
- Observational data on bone density or fracture outcomes in patients treated with IL-23 inhibitors
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.